AboutUsIntro

OUR MISSION:

“To provide accurate, affordable screening tools for the early detection of heart disease through continuous development of innovative electrocardiography.”

The Problem

Heart Disease Is The Leading Cause Of Death Worldwide

10-leading-causes-img

US Healthcare Costs in Billions                                                       

healthcare-costs-billions-img

Cardiac Testing Today

Investor_CardiacTest

Asymptomatic Patient Screening

  • Not done on a routine basis because effective low cost tools are not readily available

Symptomatic Patient

  • ECG Test – Lack of sensitivity as a screening test but used regularly to determine if a heart attack has taken place $50-$200
  • ECG based stress test – Improved sensitivity over standard ECG $250+
  • CT Scan – Used for obtaining a calcium score $200+
  • CT based Angiogram – An alternative to nuclear stress test $600+
  • Nuclear Stress Test – Test showing blood flow to the heart tissue $600+
  • Echocardiogram – Used for detecting structural abnormalities $500+
  • Invasive Angiogram – Gold standard for detecting CAD $5,000+

Lack of Innovation

  • ECG invented before electronics, computers, and software (Circa 1903)
  • Medical community has many established practices and procedures using traditional ECG technology
  • Technology until recently was not available to properly analyze additional signal data that has been present
  • Skills necesary to innovate in this area require multiple disciplines that include mathematics, programming, and a deep knowledge of cardiac function
  • Significant research required to assess the value of using other waveforms and metrics to provide valuable clinical information

Our Solution

MyoVista is a low cost, accurate screening test to assist in the assessment of heart disease

MyoVista is an important new screening tool for leading cause of death and largest spend area in healthcare

Effective screening can help shift focus to earlier lower cost treatments and better patient outcomes

Targeting the Diagnostic gap – a lack of high quality tools for effective low cost heart screening

MyoVista – Simple, non-invasive, electrophysiology based medical device with innovative and intuitive user interface

$10M and 10 years of time investment to date

R&D is complete – MyoVista fully developed and now moving into production with units shipping early 2017

box

Incorporates Standard ECG

  • Produces conventional ECG tracing with interpretive software and MyoVista report
  • Familiar lead placement – no re-training
  • Ideal screening tool
  • Physician reimbursement
  • R&D completed

Targeting the Diagnostic Gap

  • Assists in reducing unnecessary expensive testing
  • Proper screening lowers overall Healthcare costs
  • Beneficial for GP and Cardiologist

Our History

our-history

2008

  • HTL formed as Texas based C corp in 2008

2008-2012

  • Significant funding begins
  • Increase in R&D spending including new prototype unit and final informatics
  • July 2012 patent granted on overall unit

2013-Current

  • Management transition from R&D to experienced operational team – June 2013
  • Ready company for production phase
  • Raise capital for production

Executive Profiles

ANDREW SIMPSON

Chairman

Andrew has extensive experience running and growing companies, as well as fund raising and M&A. He was the Group CEO of Peel Holdings, a large private company that controls over $15 billion of assets. He successfully achieved the strategic restructuring of the group by strengthening and creating new management teams; introduced key partners in several divisions involving $3 billion of investment; and successfully managed $5 billion of debt funding across multiple facilities. His tenure saw material asset growth and an increase in liquid assets by $1 billion. Prior to that, Andrew was Group Commercial Director and divisional CEO for a large U.K listed company which grew to $500 million in revenue and saw its stock quadruple in value during his involvement. He spent eight years working as an Investment Banker with Rothschild, generally focusing on growth businesses, and qualified as a Chartered Accountant with Price Waterhouse.

 

MARK HILZ

CEO and Board Member

Mark has over 30 years’ experience as a President/CEO of multiple successful start-up companies and has a track record of succeeding with new technologies. He was CEO of INX a technology infrastructure consulting company that he founded as a startup subsidiary for a public company. It grew to $400 million in revenue with 15 offices, 2,000 customers, and 500 employees. The company was a NASDAQ listed company and was successfully sold to a private equity group in December 2011. Prior to that, Mark founded and ran as CEO, a technology logistics outsourcing firm that grew to over $160M in revenue with 1,100 employees in an 8 year span and was successful in taking the company public in an IPO as a NASDAQ listed company.

 

Brian L. Allen

Senior Vice President Business Development

Brian has 20 plus years of medical device experience that includes an accomplished track record of multiple first-to-market medical device innovations by developing strategies and building successful sales teams that achieved successful market adoption. Recently, Brian served as Vice President of Sales and Commercial Marketing for OrthoSensor Inc., where he led the planning and successful launch of their global sales and market expansion through distribution partners. Prior to that, he led the company’s domestic sales strategy, and was responsible for launch which included sales, marketing and market education of VERASENSE; the orthopedic industry’s first Sensor-assisted technology used in Total Knee Replacement Surgery
Before joining OrthoSensor, Brian served as Director of Sales and Marketing for MAKO Surgical Corp. responsible for planning and executing the commercial market launch and sustainable growth of the orthopedic industry’s first Robotic-assisted Surgery system and novel implants. MAKO Surgical Corp. was acquired by Stryker Inc. for $1.65B (2013)
Early in his career, Brian held various progressive sales and leadership roles at Medtronic Neurological and Coronary Vascular business units, Zimmer Inc. and Burrows Inc., which subsequently was acquired by Owens and Minor, Inc.

 

PAUL KLOTZ

Senior Vice President Operations

Paul has over 25 years’ experience as a senior operations executive enabling both public and privately held companies to rapidly maximize top-line growth and profitability by building scalable, efficient organizations that balance the pace of change while effectively managing risk. Paul has successfully built and operated complex, high-growth businesses across multiple industries and geographies, including, technology distribution, consumer products design, manufacturing and distribution, technology service logistics, and technology infrastructure consulting and managed services. Paul also serves on the board of directors for The Children’s Advocacy Center for Denton County.

 

AARON PETERSON

Vice President Research and Development

Aaron has 23 years of Engineering and Product Development experience, including 17 years in the Medical Device industry. Aaron has successfully productized multiple innovative technologies in the areas of Cardiac Rhythm Management, Neurostimulation and electrocardiography based devices. Specifically, Aaron has commercialized new product concepts such as Cardiac Resynchronization Therapy, Remote Patient Monitoring, and 32-channel Spinal Column Stimulation. His leadership experience includes over 15 years managing diverse teams from multiple Engineering disciplines including Systems Engineering, Software Engineering, Electrical Engineering, Mechanical Engineering, Software and Systems Verification, Systems Integration / Continuous Integration, and Test Automation. Aaron is a certified Project Management Professional (PMP) with the Project Management Institute (PMI), and has held an active certification since 2005. He is well versed in Design Controls and customizing product development processes to meet the needs of the business while still remaining compliant with the standards and regulations in the medical device industry. Aaron has received numerous awards throughout his career for his technical contributions as well as for Quality and Process Improvement initiatives.

 

Board Members

Andrew Simpson

Chairman

Mark Hilz

CEO

DR. RICHARD GRAY

Clinical Advisor and Board Member

Dr. Richard Gray joined Tyler Heart Institute as medical director in 2009. Dr. Gray specializes in valvular heart disease and artificial heart valves, coronary artery disease, and preventive cardiology. He is board certified in both internal medicine and cardiovascular disease.  He received his medical training at the University of Texas, San Antonio, and completed his residency with the VA Greater Los Angeles Health Care System. Prior to joining the medical team at Cedars-Sinai Medical Center in Los Angeles, he completed an internship at the University of Vermont – Fletcher Allen Health Care and a fellowship at  Cedars-Sinai Medical Center.  As a cardiologist since 1975, Dr. Gray has focused his career on academic medicine, teaching, research, program development, and leadership as well as clinical medicine.  Since 2002, Dr. Gray has been the medical director of Sutter Pacific Heart Centers at California Pacific Medical Center in San Francisco and Marin General Hospital in Marin County, California.  From 1996 to 2002, Dr. Gray was chief of cardiology at Regions Hospital of St Paul Minnesota and director of Cardiovascular Services for Health Partners of Minneapolis-St. Paul, and from 1992 to 1996, professor and chair of the Department of Medicine at the University of North Dakota School of Medicine.  From 1975 to 1993 he was staff associate cardiologist at Cedars-Sinai Medical Center, Los Angeles, California, serving from 1982 to 1992 as the director of Surgical Cardiology and from 1988 to 1990 he was the medical director of the Heart Transplant program at Cedars Sinai. Since 1977, Dr. Gray has been involved in numerous medical device development projects involving very early stage and small start-up as well as established corporate level activity. He has held appointments as professor of medicine at the University of California School of Medicine in Los Angeles, University of Minnesota, and at the University of North Dakota School of Medicine.  He has been principal investigator on many cardiac research studies and has authored numerous peer review publications, abstracts, book chapters, and a textbook. Dr. Gray has been actively involved in the American Heart Association and the American College of Cardiology throughout his professional career. In 1991 he served as president of the former greater Los Angeles affiliate, and has served in various leadership capacities at the former Dakota affiliate, Northland affiliate, and recently, the San Francisco division board and is currently the Western States affiliate president-elect.

John D. Owen

Board Member

Mr. Owen is a full time private investor with a particular interest in the medical device sector and is an existing investor in Heart Test Labs. He has extensive experience in high growth start-ups and in securing investment from both private and public capital sources including IPOs. He will be a welcome addition to the Board as we position HTL for rapid growth and major institutional involvement in 2017. John will Chair the Audit Committee of HTL’s Board.

Prior to John’s focus on private investment, he was most notably a co-founder of JetBlue Airways and was its CFO from inception in 1999 through 2006. During his tenure JetBlue went from a start-up to a successful NASDAQ-listed company with over $2 billion in revenue. John managed multiple public and private funding rounds as well as its IPO. Subsequently he acted as CFO and adviser to Volotea Airlines during its start-up which included raising €65 million in equity financing prior to its commencement of flight operations in 2012. We are delighted to have John join as a Director. He holds a BA in Economics from SMU, summa cum laude and Phi Beta Kappa, and an MBA in Finance from the Wharton School where he was a Mayer Fellow.

BRIAN SZYMCZAK

Board Member

Brian Szymczak is the lead attorney for Apollo Endosurgery, Inc. in Austin, Texas where he serves as Director of Legal Services. In this role Mr. Szymczak manages legal disputes and litigation matters and provides general legal counsel to the company’s leadership, sales, operations, R&D and human resources groups. Prior to working at Apollo, Mr. Szymczak served as Associate General Counsel and Director of Legal Affairs for a large surgical device manufacturer and previously worked as an associate at the law firm of Baker Botts, LLP where he counseled clients on patent and other intellectual property matters in a variety of technological fields. Mr. Szymczak is a 1999 graduate of Duke University, School of Law and holds a Bachelor of Science in Mechanical Engineering from Texas A&M University.

 

Clinical Advisors

Dr. Richard Gray

DR. PARTHO SENGUPTA

Dr. Sengupta is the Director of Cardiac Ultrasound Research and Core Lab and an Associate Professor of Medicine in Cardiology at Mount Sinai’’s Zena and Michael A. Wiener Cardiovascular Institute and the Marie-Josée and Henry R. Kravis Center for Cardiovascular Health.

Dr Sengupta graduated as a cardiology fellow from All India Institute of Medical Sciences in New Delhi and then completed his clinical residency and cardiology fellowship from Mayo Clinic Rochester and Arizona respectively. He has over 100 peer-reviewed publications that have focused on the analysis of structure, function, and flow patterns in the cardiovascular system. The primary goal of his research is to detect early stages of cardiovascular disease using state-of-the-art cardiac ultrasound technologies.

DR. JAMES TERRY

Dr. James Terry, past President of the Tarrant County Academy of Family Physicians (TCAFP) has been practicing medicine since 1987. He earned his M.D. from UT Southwestern in 1984, and has held numerous leadership roles throughout his career. Dr. Terry has served as the former President of Health Partners Medical Group, and Chief Quality Officer for Texas Health Physicians’ Group (THPG). Currently a member of Texas Academy of Family Physicians (TAFP), he also serves as diplomat of American Academy of Family Physicians (AAFP), in addition to caring for his patients at Mid-Cities Family Care in Bedford, Texas.

Advisors

DREW DIAZ

Cofounder

Drew is a cofounder of HTL and was its CEO during the development phase of the MyoVista. He has over twenty six years’ experience in the domestic and international medical device business. Drew is also the cofounder of Foundation I-4 which is dedicated to the advancement of cardiac imaging technology. He was Senior Vice President of Global Sales for Criticare Systems Inc., a US based manufacturer of anesthesia, cardiac and patient monitoring equipment. Drew also held positions with IBM, Pfizer, and DeRoyal Industries, and was the Managing Director and President of Medical Logistics GMbH, a medical device company in Germany. Drew has worked and lived in various countries and has experience in opening new markets and driving revenue via distribution networks, which will be an important part of the growth of HTL. Drew currently sits on the Board of Directors for Bone Solutions Inc., an orthopedic biologics technology company based in Dallas Texas.